Medpace director Ashley Keating resigns; Dr. Dani Zander elected to board

Medpace Holdings, Inc.

Ashley M. Keating resigned from the Board effective June 30, 2024, with no disagreement on operations, policies, or practices.
Dr. Dani S. Zander elected as Class III director effective July 1, 2024, and appointed to the Nominating and Governance Committee.
Dr. Zander is Chair of Pathology at University of Cincinnati, formerly at Penn State, and has served as president of multiple pathology societies.
Dr. Zander received an option to purchase 824 shares at the July 1, 2024 closing price, with a 7-year term, under standard non-employee director compensation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ashley M. Keating

Director

MEDP · Medpace Holdings, Inc.

Effective: 2024-06-30
Successor: Dani S. Zander
Filed: July 3, 2024, 7:59 PM ET

On June 28, 2024, Ashley M. Keating, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of her resignation, effective as of June 30, 2024.

Appointed

Dani S. Zander

Director

MEDP · Medpace Holdings, Inc.

Effective: 2024-07-01
Filed: July 3, 2024, 7:59 PM ET

The Board of the Company following a recommendation from the independent directors of the Board, unanimously approved that Dr. Dani S. Zander be elected to fill the Class III director vacancy on the Board of the Company, effective July 1, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ashley M. Keating resigned as Director at Medpace Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 28, 2024, Ashley M. Keating, a member of the Board of Directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) notified the Company of her resignation, effective as of June 30, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dani S. Zander was elected as Director at Medpace Holdings, Inc..

Action: elected
Role: Director

Exact text from the filing

The Board of the Company following a recommendation from the independent directors of the Board, unanimously approved that Dr. Dani S. Zander be elected to fill the Class III director vacancy on the Board of the Company, effective July 1, 2024

View on SEC.gov

Medpace Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-175077

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.